Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The clinical trial is a randomized, multicenter, open‐label, parallel‐group, Phase 4 study conducted to evaluate the non‐inferiority of Sarpogrelate SR 300mg once daily compared to Sarpogrelate 100mg three times daily in patients having intermittent claudication among chronic artery occlusive disease. Eligible patients who sign the informed consent form voluntarily will receive the investigational products. Subsequently, they will undergo observation and various assessments at the 12‐week and 24‐week visits. The trial is designed to determine whether Sarpogrelate SR 300mg once daily is inferior to Sarpogrelate 100mg three times daily in terms of changes in the Ankle‐Brachial Index (ABI).
Epistemonikos ID: 6dcb802bd30cefe6c999ccecea4c8e1ba6cc4ba7
First added on: May 15, 2024